Divine Aleru, Microbiome Signatures Research Coordinator

This review summarizes evidence that diet, prebiotics, and drugs such as metformin can increase Akkermansia muciniphila, a mucus-associated bacterium linked to improved metabolic health and reduced inflammation.

This study shows that live Akkermansia muciniphila protects against diet-induced obesity by selectively remodeling intestinal mucus glycan composition and barrier gene expression, rather than altering overall microbiome structure.

This study shows how gut bacterial mucinases precisely cleave O-glycan-rich glycoproteins using specialized structural adaptations, enabling controlled mucus turnover while preserving barrier function and explaining how mucin-degrading microbes can be beneficial or harmful depending on context.

This study shows that Akkermansia muciniphila uses dietary polyphenols as iron carriers, enabling growth under iron limitation and outcompeting pathogenic bacteria through advanced iron acquisition systems.

This review highlights Akkermansia-derived extracellular vesicles as powerful regulators of gut barrier function, immune balance, metabolism, and cancer response, positioning them as promising cell-free microbiome therapeutics.

This study shows that Akkermansia muciniphila survives gastrointestinal stress through aggregation, adheres preferentially to mucus-secreting intestinal cells, and interacts with human mucins via specific proteins, supporting its therapeutic potential while highlighting dose-dependent safety considerations.

This review explains how Akkermansia muciniphila proteins, not just the bacterium itself, regulate immunity, metabolism, gut barrier integrity, cancer response, and neuroinflammation, highlighting their emerging role as next-generation postbiotic therapeutics.

This review explains how mucin-degrading gut bacteria regulate barrier integrity, immunity, and disease risk in a context-dependent manner. It highlights why microbes such as Akkermansia muciniphila can be protective or harmful depending on diet, strain, and host immune status.

This study shows that Akkermansia muciniphila produces a uniquely structured lipooligosaccharide that preferentially activates anti-inflammatory TLR2 signaling while limiting TLR4-driven endotoxin responses. The findings explain how this Gram-negative symbiont supports immune balance and metabolic health.

This review explores when mucus degradation by Akkermansia muciniphila supports gut health and when it harms barrier integrity. Evidence shows its effects depend on host context, microbial balance, and mucus renewal capacity, reframing it as a condition-dependent microbiome signal rather than a universal probiotic.

This study shows that excessive Akkermansia muciniphila colonization damages the intestinal mucus barrier and tight junctions in colorectal cancer models, worsening inflammation and disease progression. Findings highlight its role as a context-dependent microbe rather than a universally beneficial probiotic.

This review summarizes evidence that Akkermansia muciniphila reduces inflammation and improves metabolic health by strengthening the gut barrier and regulating immune signaling. Findings support its role as a next-generation probiotic for obesity, diabetes, and related inflammatory conditions.

This review shows that Akkermansia muciniphila protects against bacterial and viral infections by strengthening gut barriers and regulating systemic immunity. Evidence supports its role as a next-generation probiotic with effects extending beyond metabolism into infection and immune resilience.

This study shows that antibiotics can select Akkermansia muciniphila variants that lose their ability to protect against obesity and metabolic dysfunction. The findings reveal a direct mechanistic link between antibiotic exposure, altered microbiome function, and chronic metabolic disease risk.

This study shows that human-derived Akkermansia muciniphila strains carry limited, mostly nonfunctional antibiotic resistance traits. Phenotypic testing confirms low risk of transferable resistance, supporting its safety as a next-generation probiotic and microbiome biomarker.

This review explains how Akkermansia muciniphila supports gut barrier integrity, immune balance, and metabolic health. Evidence highlights its role as a key microbiome signal across obesity, inflammation, and aging, with postbiotic strategies showing strong clinical promise.

This review synthesizes evidence showing Akkermansia muciniphila supports gut barrier integrity, immune balance, and metabolic health through mucin degradation, SCFA production, and bioactive proteins, with emerging human trials confirming safety and therapeutic promise.

What was reviewed? This review synthesized experimental, translational, and clinical evidence describing the biological functions of Akkermansia muciniphila in intestinal-related diseases. The authors evaluated how this mucin-degrading bacterium contributes to intestinal homeostasis, immune regulation, and metabolic balance, with emphasis on mechanistic pathways rather than descriptive abundance alone. The review integrated findings on live bacteria, pasteurized […]

This review examines how Akkermansia muciniphila shapes gut immune signaling to reduce inflammation, obesity, and diabetes risk. Evidence shows that its abundance and derived proteins strengthen the intestinal barrier, suppress pro-inflammatory cytokines, and improve metabolic outcomes across experimental models and early human trials.

This review maps where Akkermansia muciniphila appears across the human gut and beyond, from early infancy to old age. Evidence links higher abundance with stronger mucus-barrier function and better metabolic health, while lower levels track with IBD, appendicitis severity, obesity, and dysglycemia.

Listeria monocytogenes is an opportunistic pathogen capable of surviving in diverse environments, including soil, water, and decaying vegetation. L. monocytogenes has the unique ability to evade the immune system by moving directly from cell to cell within the host. This intracellular lifestyle allows the bacterium to avoid extracellular immune detection, contributing to its ability to cause invasive diseases like meningitis and septicemia, particularly in the elderly and immunocompromised.

This study explores the virulence mechanisms of Listeria monocytogenes, focusing on its surface proteins and iron acquisition systems, shedding light on potential therapeutic interventions and food safety strategies.

This study demonstrates that bacteriophage P100 is a safe and effective biocontrol agent for reducing Listeria monocytogenes in soft cheeses, offering a promising alternative to traditional antimicrobial agents.

This study demonstrates that the FOP bacteriophage cocktail effectively reduces Listeria monocytogenes levels in the gastrointestinal tract, without disturbing the gut microbiota, offering a promising alternative to antibiotics for treating or preventing Listeria infections.